在线办公
期刊论坛
主 管
中国人民解放军总医院
主 办
中国人民解放军总医院老年心血管病研究所
中国科技出版传媒股份有限公司
编 辑
中华老年多器官疾病杂志编辑委员会
100853, 北京市复兴路28号
电话:010-66936756
传真:010-66936756
E-mail: zhlndqg@mode301.cn
创刊人 王士雯
总编辑 范利
副总编辑 陈韵岱
执行主编 叶大训
编辑部主任 王雪萍
ISSN 1671-5403
CN 11-4786
创刊时间 2002年
出版周期 月刊
邮发代号 82-408
友情链接
任浩进,黄莉芳,王丽岳.比伐芦定在冠心病合并终末期肾病患者行经皮冠状动脉介入治疗术中的抗凝效果[J].中华老年多器官疾病杂志,2021,20(6):444~448
比伐芦定在冠心病合并终末期肾病患者行经皮冠状动脉介入治疗术中的抗凝效果
Anticoagulant effect of bivalirudin in patients with coronary heart disease and end-stage renal disease during percutaneous coronary intervention
投稿时间:2020-08-17  
DOI:10.11915/j.issn.1671-5403.2021.06.092
中文关键词:  冠心病;终末期肾病;肾小球滤过率;比伐芦定;肝素
英文关键词:coronary heart disease; end-stage renal disease; glomerular filtration rate; bivalirudin; heparin Corresponding author:WANG Li-Yue,E-mail:l453427820@163.com.〖FL
基金项目:
作者单位E-mail
任浩进 武汉市普仁医院心血管内科,武汉430081 l453427820@163.comanticoagulant 
黄莉芳 武汉市普仁医院心血管内科,武汉430081 l453427820@163.comanticoagulant 
王丽岳 武汉市普仁医院心血管内科,武汉430081 l453427820@163.comanticoagulant 
摘要点击次数: 216
全文下载次数: 228
中文摘要:
      目的 回顾性分析比伐芦定与肝素用于冠心病(CHD)合并终末期肾病(ESRD)患者经皮冠状动脉介入治疗(PCI)术中的抗凝效果。方法 选择2015年10月至2018年12月在武汉市普仁医院接受PCI治疗的62例CHD合并ESRD患者为研究对象,根据术中给予抗凝药物的不同,将患者分为对照组(肝素)29例和观察组(比伐芦定)33例。比较2组住院期间造影剂肾病(CIN),术后30d及1年净临床不良事件(NACE)、主要不良心脑血管事件(MACCE)及全部出血事件发生情况;观察2组MACCE分项指标的差异。采用SPSS 25.0统计软件对数据进行分析,根据数据类型,分别采用t检验或χ2检验。结果 住院期间2组各发生CIN 3例,差异无统计学意义(P>0.05)。术后30 d,观察组NACE与全部出血事件发生率均低于对照组,差异有统计学意义(P<0.05);2组MACCE发生率比较,差异无统计学意义(P>0.05)。术后1年,观察组NACE发生率低于对照组,差异有统计学意义(P<0.05);2组MACCE、全部出血事件发生率差异无统计学意义(P>0.05)。结论 CHD合并ESRD患者行PCI治疗,与肝素相比,比伐芦定能显著减少术后30d NACE 及全部出血事件,抗凝效果良好,且NACE减少优势持续至术后1年。比伐芦定更适合 CHD合并ESRD患者PCI术中抗凝。
英文摘要:
      Objective To retrospectively analyze anticoagulant effect of bivalirudin and heparin in the patients with coronary heart disease(CHD) and end-stage renal disease(ESRD)during percutaneous coronary intervention(PCI). Methods A total of 62 patients with CHD complicated with ESRD were selected for the study, who received PCI treatment in Wuhan Puren Hospital from October 2015 to December 2018. According to the different anticoagulants administered during operation, they were divided into control group (heparin, n=29) and observation group (bivalirudin, n=33). The two groups were compared in contrast-induced nephropathy (CIN) during hospitalization, net adverse clinical events (NACE) and major adverse cardiac and cerebrovascular events (MACCE) in 30 days and 1 year after operation. The difference of MACCE sub-indexes between the two groups was observed. SPSS statistics 25.0 was used for data analysis, and t-test or Chi-square test was used for comparison between groups. Results During hospitalization, 3 patients developed CIN in both groups without significant difference (P>0.05). At 30 days after the operation, NACE and all bleeding events in the observation group were lower than those in the control group, and the differences were significant (P<0.05). There was no significant difference in MACCE between the two groups (P>0.05). At postoperative 1 year, NACE was significantly lower in the observation group than the control group (P<0.05), and there was no significant difference in MACCE and all bleeding events between the two groups (P>0.05). Conclusion Bivalirudin reduces the NACE and all bleeding events more significantly than heparin within 30 days after PCI in CHD patients with ESRD, showing better anticoagulant effect. The advantage of risk reduction of NACE may last till 1 year after PCI. Bivalirudin is more suitable for anticoagulation in patients with CHD and ESRD during PCI.
查看全文    下载PDF阅读器
关闭